Amneal Pharmaceuticals, Inc. (AMRX) company profile

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generic, biosimilar, and proprietary branded pharmaceutical products. Its operations are organized into three principal segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment supplies retail generics, sterile injectables, and biosimilars covering a wide range of dosage formulations. The Specialty segment focuses on proprietary branded therapeutics addressing central nervous system conditions, such as Parkinson's disease, and endocrine disorders. Through AvKARE, the company repackages and distributes pharmaceuticals, over-the-counter medications, and medical supplies. Customers include drug wholesalers, retail and mail-order pharmacies, healthcare institutions, and United States governmental bodies.

The enterprise conducts its business primarily across the United States, India, and Ireland, maintaining a network of manufacturing facilities, research and development laboratories, and distribution centers. Its facilities include regional distribution hubs located in Kentucky and Pennsylvania, serving approximately 1,300 commercial, institutional, and government accounts. The provided text details operations in the United States, India, and Ireland, but does not disclose a specific corporate headquarters location.

Summary of the business section of Amneal Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we had over 8,500 employees (“Amneal Employees”), excluding approximately 200 employees in our AvKARE segment.”